The specter of generic challenges has repeatedly loomed above copyright’s iconic drug, Sildenafil, sparking questions about the prospects of related escort drug holdings. While early periods saw substantial gains, the patent end has opened the path for less expensive alternatives, possibly reducing earnings and posing a significant danger for inv